http://seekingalpha.com/article/293795-focus-on-entereg-reiterating-buy-on-adolor?source=yahoo
I upgraded Adolor (ADLR) to a BUY after the company announced that it had reacquired all rights to Entereg from GlaxoSmithKline (GSK). I did this even though binary phase II data on ADL 5945, its new drug for opioid induced constipation, was due at any time. I felt that the stock was attractive on the basis of Entereg alone, and this induced me to take the risk of being in front of an important data release. I was holding my breath, but fortunately of phase II data on ADL 5945 was very positive.
I am now carefully watching two key events to see how they unfold:
The transition of Entereg from a co-marketing agreement with Glaxo to Adolor assuming all responsibility for marketing.
The second key event is the progress of partnering discussions on ADL 5945. I recently attended an investor conference and spoke with Adolor’s management on these two issues. I was encouraged by their responses and I am reiterating my Buy recommendation.
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM